Het VISTA onderzoek:Het VTE-predictiemodel als leidraad voor de duur van antistollingstherapie binnen de huidige richtlijnen voor patiënten met een veneuze-tromboembolie.

• Conditions: (Recurrent) Venous thromboembolism; Deep vein thrombosis; Pulmonary Embolism; (recidief) veneuze trombo-embolie; diep veneuze trombose; longembolie; VKA treatment duration; recurrent VTE prediction model

• Registration Number: NL-OMON25558
• Lead Sponsor: trecht University/ Utrecht University Medical Center

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 1500

Inclusion Criteria

1. First unprovoked VTE;

2. Legal age (>18 years).

Exclusion Criteria

1. Treatment indication VKA of at least 1 year
ie. recurrent VTE; atrial fibrillation; prosthetic valve;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Recurrent VTE during 24 months of follow-up after the initial 6 months of VKA treatment. VTE is defined as proximal DVT and/or fatal or non-fatal PE as confirmed by compression US for DVT and by (spiral CT) angiography and/or ventilation-perfusion lung scanning for PE.

Secondary Outcome Measures

Name	Time	Method
1. The occurrence of major bleedings;<br /><br>2. Quality of life (based on QoL questionnaires at T=12 and T=24 months);<br /><br>3. Cost-effectiveness (at T=24 months using a Markov decision model).